Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

Tytuł :
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Index Terms :
Immunologie
Adjuvants, Immunologic -- adverse effects -- pharmacology -- therapeutic use
Aged
Antigens, CD27 -- metabolism
Antigens, CD45 -- metabolism
Breast Neoplasms -- blood -- immunology -- therapy
Cell Proliferation -- drug effects
Chemokines -- blood
Cytokines -- blood
Diphosphonates -- adverse effects -- pharmacology -- therapeutic use
Disease Progression
Esterases -- metabolism
Female
Hemiterpenes -- pharmacology
Humans
Imidazoles -- adverse effects -- pharmacology -- therapeutic use
Immunotherapy -- methods
Interferon-gamma -- metabolism
Interleukin-2 -- adverse effects -- pharmacology -- therapeutic use
Lymphocyte Activation -- drug effects
Lymphocyte Count
Lysine -- analogs & derivatives -- metabolism
Middle Aged
Mucin-1 -- blood
Organophosphorus Compounds -- pharmacology
Receptors, Antigen, T-Cell, gamma-delta -- metabolism
Remission Induction
Salvage Therapy
T-Lymphocyte Subsets -- cytology -- drug effects -- immunology -- metabolism
TNF-Related Apoptosis-Inducing Ligand -- metabolism
Treatment Outcome
cytokines
cytotoxicity
immunotherapy
metastatic breast cancer
Vγ9Vδ2 T cells
info:eu-repo/semantics/article
info:ulb-repo/semantics/articlePeerReview
info:ulb-repo/semantics/openurl/article
Wydawca :
2010-08
Dodane szczegóły :
Meraviglia, S
Eberl, M
Vermijlen, David
Todaro, M
Buccheri, S
Cicero, G
La Mendola, C
Guggino, G
D'Asaro, M
Orlando, V
Scarpa, F
Roberts, Allen
Caccamo, N
Stassi, G
Dieli, F
Hayday, A C
Typ dokumentu :
Zasób elektroniczny
URL :
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/115752">http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/115752
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL">http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLL
Dostępność :
Open access content. Open access content
2 full-text file(s): info:eu-repo/semantics/restrictedAccess | info:eu-repo/semantics/restrictedAccess
Pozostałe numery :
EQY oai:dipot.ulb.ac.be:2013/115752
uri/info:doi/10.1111/j.1365-2249.2010.04167.x
uri/info:pii/CEI4167
uri/info:pmid/20491785
uri/info:scp/77954652637
uri/info:pmcid/PMC2909411
https://dipot.ulb.ac.be/dspace/bitstream/2013/115752/6/PMC2909411.pdf
https://dipot.ulb.ac.be/dspace/bitstream/2013/115752/5/115752.pdf
803496879
Źródło wspomagające :
UNIV LIBR DE BRUXELLES
From OAIster®, provided by the OCLC Cooperative.
Numer akcesji :
edsoai.ocn803496879
Zasób elektroniczny
The potent anti-tumour activities of gammadelta T cells have prompted the development of protocols in which gammadelta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a Vgamma9Vdelta2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of Vgamma9Vdelta2 T cells in all patients. However, a statistically significant correlation of clinical outcome with peripheral Vgamma9Vdelta2 T cell numbers emerged, as seven patients who failed to sustain Vgamma9Vdelta2 T cells showed progressive clinical deterioration, while three patients who sustained robust peripheral Vgamma9Vdelta2 cell populations showed declining CA15-3 levels and displayed one instance of partial remission and two of stable disease, respectively. In the context of an earlier trial in prostate cancer, these data emphasize the strong linkage of Vgamma9Vdelta2 T cell status to reduced carcinoma progression, and suggest that zoledronate plus low-dose IL-2 offers a novel, safe and feasible approach to enhance this in a subset of treatment-refractory patients with advanced breast cancer.
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
FLWIN
SCOPUS: ar.j
info:eu-repo/semantics/published

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies